DOCSLIB.ORG

Cphi China 2020 第二十届世界制药原料中国展

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Cphi China 2020 第二十届世界制药原料中国展 20 Years of Uniting Chinese Pharma with the Global Market CPhI China 2020 第二十届世界制药原料中国展 2020年6月22-24日 上海新国际博览中心（浦东） 亮点活动 · 展商名单 · 优势产品 · 资格认证 · 出口情况 ShowShow PreviewPreview 展览快讯展览快讯 关注展会官微 共谋行业发展 Co-located with 同期举办: 第十五届世界制药机械、 www.cphi-china.com 包装设备与材料中国展 www.cphi.com/china Contents 目录 Concentrate the Strength of National Medicine Innovation and Empower Chinese Pharmaceuticals to Stand Out in a Global Market 凝聚民族医药创新力量，吹响中国制药国际化号角 Foreword 前言 Event Brief 展会主要信息 CPhI China · Exhibitor List & Introduction 世界制药原料中国展 · 展商名单及介绍 PharmaExcipients China · Conference · Exhibitor List & Introduction 国际药用辅料与技术中国展· 会议 ·展商名单及介绍 NEX China · Conference · Activity · Exhibitor List & Introduction 世界天然提取物中国展 · 会议 · 活动 · 展商名单及介绍 ICSE China · Conference · Exhibitor List & Introduction 世界医药合同定制服务中国展 · 会议 · 展商名单及介绍 bioLIVE China · Conference · Exhibitor List & Introduction 世界生物医药科技中国展 · 会议 · 展商名单及介绍 P-MEC, InnoPack & LABWorld China · Exhibitor List 制药机械、包装设备与材料中国展 · 展商名单 Foreword 前 言 On 22-24 June 2020, CPhI China 2020, co-located with ICSE China, NEX China, and P-MEC China, will continue its glorious journey and celebrate its 20th anniversary at Shanghai New International Expo Centre (SNIEC). CPhI China 2020年6月22-24日，“第二十届世界制药原料中国展”（CPhI China）将携手“第八届世界医 was initiated as the showcase of APIs and has gradually developed into a large-scale comprehensive service 药合同定制服务中国展”（ICSE China），“2020世界天然提取物展”（NEX China）以及“第十五 platform connecting the entire pharmaceutical industry chain. It has borne witness of the ever-reforming pharma 届世界制药机械、包装设备与材料中国展”（P-MEC China）在上海新国际博览中心再续辉煌征程， industry, trailed every pace of growth and progress of the pharma manufacturers, and has been walking along with China’s medical & pharma industry since the very beginning, sharing all the ups and downs, tears and glo- 迎来熠熠生辉的二十周年华诞。CPhI China以原料药产品展示起步，逐渐发展成如今串联整个制药全 ries. In year 2020, CPhI & P-MEC China will embrace a brand-new epoch of med & pharma, with record-breaking 产业链的大型综合服务平台，见证着制药行业一步步的变革，铭刻了制药企业做大做强的轨迹，自始 figures in show scale and visitor numbers: the show is to cover an exhibition area of 210,000 square meters and is 至终与中国医药工业相携相守，共生共荣。2020年，CPhI & P-MEC China将迎来一个非凡的医药新纪 expected to draw 3,400+ exhibitors from over 140 countries and regions and 75,000+ visits from global industry professionals, to mark the grand occasion of its 20th anniversary. 元，而随之而来的是进一步提升的展示规模和爆发式增长的观众数量：展览规模将达到21万平方米， 吸引3,400余家国内外展商和来自140多个国家及地区的逾75,000人次专业观众，共同见证展会二十 Looking back as we move forward, the past 20 years of China’s pharma industry has witnessed dramatical chang- 周年华彩绽放！ es: from ‘copy’ to ‘create’, from ‘quantity’ to ‘quality’, China’s pharma industry is experiencing its golden age of development, and the Chinese pharma professionals are faced with unprecedented opportunities. Remaining true to its original aspiration and keeping its mission firmly in mind, CPhI China has been always fostering industry 回首中国医药行业这激荡的二十年，从仿到创，从追量到求质，中国医药正经历着发展的黄金 development with focused, deep and innovative perspectives. The show covers 14 segmentations representing 期，中国制药人也迎来了难得的发展机遇。跟随时代发展步伐，CPhI China不忘初心，砥砺前行，始 all sectors over the industry layout, including APIs, intermediates and fine chemicals, pharma excipients, fin- ished dosages, CMOs & CROs, biopharmaceuticals, natural extracts, animal health & feed, pharma machinery, 终以聚焦、深耕、创新的定位推进产业发展，目前展会已囊括制药原料、精细化工与中间体、药用辅 pharma packaging materials, laboratory equipment, environmental protection and clean technology, pharma 料、制剂、合同定制、生物制药、天然提取物、兽药及饲料、制药机械、包装材料、实验室仪器、制 logistics and pharma automation & informatization. It facilitates a mutual platform for both domestic and interna- 药环保洁净、医药物流、医药自动化与信息化共十四大细分版块，为制药企业优化产业链布局、加速 tional peers to get deeply involved in optimizing the industry layout and boosting transformation and innovation. 转型创新构建了海内外深度参与的双向平台。 Since its initiation, CPhI China has been acting as a vital bond to connect Chinese pharma manufacturers with international buyers, and it has successfully helped a significant number of Chinese pharma players to explore the 自创办以来，CPhI China一直是连接中国制药企业与海外买家的重要纽带，为众多中国制药企业 global market. Every year CPhI China is welcoming an endless stream of visitors from overseas. Buyers from Europe, Americas and Africa has increased dramatically, achieving a 225% increasing rate in the recent 4 years. The 2020 走向全球打开了全新的窗口，每年来自海外的买家络绎不绝，近几年来自欧洲、美洲和非洲地区的买 show is supposed to attract more than 25,000 visits from overseas pharma professionals, providing tremendous 家更是逐年攀升，近4年更是达到了225%的增长幅度。2020年展会将吸引超过25,000人次的海外专 opportunities for domestic pharma enterprises to connect with global counterparts. In addition to the richness of 业观众到场参观洽谈，为国内药企拓展全球人脉网络添砖加瓦。除了坐拥丰富的海外买家资源，展会 overseas buyer resources, the show is also a best choice for international exhibitors. 5 country pavilions for exhibi- tors from Korea, India, Russia, Turkey and Brazil, together with other 300 overseas exhibitors from Germany, France, 也格外受到国际展商的青睐。2020年展会将在原有250余家海外参展企业、5个国家展团的基础上进 Switzerland, Italy, etc, will provide a facilitated platform for domestic enterprises to develop reliable partnerships 一步加大外商招募力度，为国内企业寻找优质合作伙伴和引进海外产品提供了便利的平台。 and to source quality products. “China Pharma Week”, as a signature hi-end event week concurrent with CPhI China, is a locus of industry “China Pharma Week”作为CPhI China每年同期特别推出的高端会议活动周，汇聚全球医 elites, innovative products and advanced technologies of the global pharma industry. Every year the Week casts 药行业大咖，全面展示国内外优质创新产品及先进技术，每年都吸引全球医药行业的聚焦，已然成 spotlights on the latest trends of the industry and acts as a top-level social networking platform for the Chinese 为中国制药企业提升国际影响力的高端社交平台。值此展会二十周年之际，主办方将在第四 pharma players to enhance their international influence. On this occasion of the 20th anniversary, the organizer will upgrade the 4th edition of “China Pharma Week” with special anniversary celebrations, to express the 届“China Pharma Week”基础上全新升级周年庆特别活动，覆盖重量级行业评选及高端晚宴，感 gratitude to all the industry peers for their company in the 20-year history of CPhI China and to share insights on 恩伴随CPhI China前行二十载的医药同行，并与全球业内高层分享行业未来发展方向。同时，还将举 the future scenario with global industry leaders. The content will cover heavy-weight industry award recognitions, 办工厂参观、创新展示秀及探索之旅、高品质行业会议及优质买家配对会等活动，集结海内外专业机 high-level networking dinners, plant visits, innovation galleries and tours, conferences and buyer sourcing events. Enormous industry resources from domestic and overseas institutions, associations and media will be integrated, 构、协会、媒体等各方资源，为制药产业链各环节人士提供优质的商业合作洽谈环境，收获高端社交 to facilitate professionals from every industry chain sector with ideal environment for business cooperation and 人脉资源。即将开启的二十周年忠实客商征集、二十周年幸运观众等创新趣味活动也无疑将为展会周 “ ” “ networking. The coming-soon themed events Call for 20 Years Loyal Exhibitors and 20th Anniversary Lucky 年庆锦上添花，届时线上线下将共同庆祝，新老朋友欢聚一堂，回顾个人及企业的成长历程，奏响行 Visitors” will definitely be the icing on the cake of the celebration. May the old and new friends gather under one roof, to share precious memories of personal experience and enterprise growth, and to compose together the new 业二十载新华章! chapter for an even more glorious 20-years ahead ! 更多展会资讯，欢迎您关注展会官网：www.cphi-china.cn。 For more information, please refer to the official show website: www.cphi-china.cn Yours sincerely, 展会主办方敬上 CPhI & P-MEC China 二零一九年九月 2 3 Various Onsite Conferences & Activities Attract Industry Elites as a High Level Platform 专业会议活动精彩呈现，打造知识分享新时代 for Business and Networking 高水准贸易社交平台汇聚业内高端人士 CPhI & P-MEC China 2019汇聚了全球优质 企业资源，助力更多制药企业扩展全球人脉网 络，同时为国内外买家高质高效贸易社交提供 了便利的平台。展会的海外观众人次逐年攀升， 近4年更是达到了225%的增长幅度，可见展 会的国际影响力愈发凸显。 China Pharma Week Plus 20th Anniversary 2020 Highlights 第四届高端社交盛宴携20周年特别活动重磅登场 活动预告 Attended by Visitors from Pharmaceutical Industry Chain 第十一届中国与世界医药企业家高峰会 制药产业链各环节人士悉数到场 （参观人次排名前六公司性质） 与400位行业大咖共同探讨在新时代下，中国医药企业 国际化的变局与未来 ................................................ 经销商/ 生物制药及 合同研发及 制药生产企业 进出口企业 医药销售公司 技术公司 制药机械 生产外包 20周年庆晚宴 16,243 10,824 9,892 5,898 3,209 2,996 感恩与CPhI China同行20载的医药同行，与全球业内 高层分享行业未来发展方向 ................................................ 2020年医药国际化百强企业评选（颁奖及展示） 以产品出口、国际注册、海外并购、国际合作等指标为 基础，评选医药国际化百强企业 ................................................ 工厂参观 High Efficient Trade Exchange with Industry Leaders “China Pharma Week”作为CPhI China每年同期特别推出的高端会议活动周，汇 帮助意向客户零距离体验供应商的制造技术，深度了解 聚全球医药行业大咖，全面展示国内外优质创新产品及先进技术，每年都吸引全球 大咖云集，搭建高端贸易社交平台（参观人次排名前五部门） 企业的制造文化，尽享趣味与实用性 医药行业的聚焦，已然成为中国制药企业提升国际影响力的高端社交平台。值此展 ................................................ 会二十周年之际，主办方将在第四届“China Pharma Week”基础上全新升级周年 采购部 点滴汇聚，20周年忠实客商征集活动 27.91% 庆特别活动，覆盖重量级行业评选及高端晚宴，感恩伴随CPhI China前行二十载 征集20年来与CPhI China同行的忠实展商和观众，开 的医药同行，并与全球业内高层分享行业未来发展方向。 启20周年系列活动 27.76% 销售部/市场部 总裁/主席/董事/总经理 22.32% Other Hot Events of 2020 12.35% 研发部 其他2020年现场热点活动会议 48.86% 9.24% 外贸部 打开走向全球的窗口，开拓转型升级新格局 汇聚制剂行业热点，接轨国际医药态势 . 中国与世界创新与发展论坛 . 中国与世界药政答疑会（法规篇） 经理/项目经理/部门主管 CPhI 生产部 . CPhI China 20周年系列特别活动（敬请期待） . 制剂国际化经验分享与交流沙龙 7.17% ................................................ ..................................... 网罗生物医药前沿科技，引领亚洲生物医药技术发展 探讨质量控制技术要求， . 2020 Bio S&T 助力辅料企业融入全球化产业链 Increased US and European Buyers Gathering for Continuous Growth in Overseas Visitor . 第七届中国生物制药峰会 . CPhI药用辅料论坛 ................................................ Pharmaceutical Annual Feast 展会国际化程度再攀新高, . CPhI中国与世界药政答疑会（辅料篇） 探索天然植物提取物全新发展方向，为健康中国助力 ..................................... 海外观众齐聚年度盛会，欧美观众比例再度提升 海外买家大幅增长（单位：人次） . 第十五届天然产物创新与发展论坛（NIC 2020） “展会+互联网”平台升级， (参观人次排名前十五海外国家) 20302 . 2020年中国植物提取物创新产品展示秀及路演 提供精准高效配对服务 776 225% ................................................ 孟加拉国 2019 . 第十届“CPhI制药在线”买家采购会 353 673 2016-2019 15329 德国 巴基斯坦 2200 2018 迎接行业高速成长下的挑战，加快合同外包国际化的步伐 . 制药在线新产品体验中心
Load more

Recommended publications
  • Yerevan State Medical University After M. Heratsi
    YEREVAN STATE MEDICAL UNIVERSITY AFTER M. HERATSI DEPARTMENT OF PHARMACY Balasanyan M.G. Zhamharyan A.G. Afrikyan Sh. G. Khachaturyan M.S. Manjikyan A.P. MEDICINAL CHEMISTRY HANDOUT for the 3-rd-year pharmacy students (part 2) YEREVAN 2017 Analgesic Agents Agents that decrease pain are referred to as analgesics or as analgesics. Pain relieving agents are also called antinociceptives. An analgesic may be defined as a drug bringing about insensibility to pain without loss of consciousness. Pain has been classified into the following types: physiological, inflammatory, and neuropathic. Clearly, these all require different approaches to pain management. The three major classes of drugs used to manage pain are opioids, nonsteroidal anti-inflammatory agents, and non opioids with the central analgetic activity. Narcotic analgetics The prototype of opioids is Morphine. Morphine is obtained from opium, which is the partly dried latex from incised unripe capsules of Papaver somniferum. The opium contains a complex mixture of over 20 alkaloids. Two basic types of structures are recognized among the opium alkaloids, the phenanthrene (morphine) type and the benzylisoquinoline (papaverine) type (see structures), of which morphine, codeine, noscapine (narcotine), and papaverine are therapeutically the most important. The principle alkaloid in the mixture, and the one responsible for analgesic activity, is morphine. Morphine is an extremely complex molecule. In view of establish the structure a complicated molecule was to degrade the: compound into simpler molecules that were already known and could be identified. For example, the degradation of morphine with strong base produced methylamine, which established that there was an N-CH3 fragment in the molecule.
    [Show full text]
  • Zurampic (Lesinurad)
    Market Applicability Market DC GA KY MD NJ NY WA Applicable X X X X X X NA Zurampic (lesinurad) Override(s) Approval Duration Prior Authorization 1 year Quantity Limit Medications Quantity Limit Zurampic (lesinurad) May be subject to quantity limit APPROVAL CRITERIA Requests for Zurampic (lesinurad) may be approved if the following criteria are met: I. Individual has had a previous trial (medication samples/coupons/discount cards are excluded from consideration as a trial) and inadequate response (unable to achieve target serum uric acid levels) to one preferred xanthine oxidase inhibitor (allopurinol, febuxostat*); AND II. Individual has hyperuricemia associated with gout; AND III. Individual is unable to achieve target serum uric acid levels while on a xanthine oxidase inhibitor (such as allopurinol or febuxostat*); AND IV. Individual remains symptomatic (such as, but not limited to joint pain, swelling, limited range of motion, erythema) despite use of xanthine oxidase inhibitor; AND V. Individual will continue use of a xanthine oxidase inhibitor in conjunction with Zurampic. *requires prior authorization Zurampic (lesinurad) may not be approved for the following: I. Individual has severe renal impairment (creatinine clearance less than 30 mL/min), end stage renal disease, is on dialysis or is a kidney transplant recipient; OR II. Individual has Lesch-Nyhan syndrome or tumor lysis syndrome. PAGE 1 of 2 08/14/2019 This policy does not apply to health plans or member categories that do not have pharmacy benefits, nor does it apply to Medicare. Note that market specific restrictions or transition-of-care benefit limitations may apply. CRX-ALL-0429-19 Market Applicability Market DC GA KY MD NJ NY WA Applicable X X X X X X NA Note: Zurampic (lesinurad) has a black box warning indicating risk of acute renal failure is more common when Zurampic is used without a xanthine oxidase inhibitor.
    [Show full text]
  • 1. Two Components, Two Sets of Lecturers
    Conditions 1. Two components, two sets of lecturers. 2. Lectures 1-5 Prof. F. Hudecz Lectures 6-9 Dr. Gy. Domány Lectures 10-12 Dr. P. Buzder-Lantos 3. Examination: two parts determined by the lecturers and one mark. - option A: written test - option B: presentation based on literature - option C: oral examination 4. Participation at lectures > 70 % [email protected] Some Approved Peptide Pharmaceuticals and their Methods of Manufacture First generatioin Second generation New generation Oxytocin (L) Carbetocin (S) Abarelix (GnRH) (L) ACTH (1-24) & (1-39) (L,S) Terlipressin (L,S) Cetrorelix (GnRH) (L) Vasopressin (L,S) Felypressin (L,S) Ganirelix (GnRH) (L) Insulin (E,SS, R) Buserelin (L,S) Eptifibatide Glucagon (E,S,R) Deslorelin (L,S) Bivalirudin (L) Calcitonins (L,S,R) Goserelin (L) Copaxone (L) TRH (L) Histrelin (L) Techtide P-289(S) Gonadorelin (L,S) Leuprolide (L,S) Cubicin (F) Somatostatin (L,S) Nafarelin (S) Fuzeon (antiHIV (H) GHRH (1-29) & (1-44) (S) Tryptorelin (L,S) Ziconotide (pain) (S) CRF (Human & Ovine) (S) Lecirelin (S) Pramlintide (diabetes) (S) Cyclosporin (F) Lanreotide (S) Exenatide (diabetes) (S) Thymopentin (L) Octreotide (L,S) Icatibant (brady-rec) Thymosin Alpha-1 (S) Atosiban (L) Romiplostim (hormon) Secretins (Human & Porcine) (E,S) Desmopressin (L,S) Degarelix (GnRH) Parathyroid Hormone (1-34) & (1-84)(S) Lypressin (L) Mifamurtide (rák, adj.) Vasoactive Intestinal Polypeptide (S) Ornipressin Ecallantide (ödéma) Brain Natriuretic Peptide (R) Pitressin (L) Liraglutide (diabetes) Cholecystokinin (L) ACE Inhibitors (Enalapril, Lisinopril) (L) Tesamorelin Tetragastrin (L) HIV Protease Inhibitors (L) Surfaxin Pentagastrin (L) Peginesatide Eledoisin (L) Carfilzomib Linaclotide (enz.inh) L = in solution; S = on solid phase; E = extraction; F = fermentation; H = hybrid synthesis; R = recombinant; SS = semi-synthesis.
    [Show full text]
  • Dissertationes Medicinae Universitatis Tartuensis 106 Dissertationes Medicinae Universitatis Tartuensis 106
    DISSERTATIONES MEDICINAE UNIVERSITATIS TARTUENSIS 106 DISSERTATIONES MEDICINAE UNIVERSITATIS TARTUENSIS 106 EPIDEMIOLOGY OF ADULT EPILEPSY IN TARTU, ESTONIA Incidence, prevalence and medical treatment ANDRE ÕUN TARTU UNIVERSITY PRESS Department of Neurology and Neurosurgery, University of Tartu, Tartu, Estonia Dissertation is accepted for the commencement of the degree of Doctor of Medical Sciences on March 22, 2005 by the Council of the Faculty of Medicine, University of Tartu, Estonia Opponent: Dr. Tapani Keränen, University of Tampere, Finland Commencement: May 4, 2005 Publication of this dissertation is granted by the Faculty of Medicine, University of Tartu ISSN 1024–395X ISBN 9949–11–034–3 (trükis) ISBN 9949–11–035–1 (PDF)) Autoriõigus Andre Õun, 2005 Tartu Ülikooli Kirjastus www.tyk.ee Tellimus nr. 142 CONTENTS LIST OF ORIGINAL PUBLICATIONS......................................................... 8 ABBREVIATIONS......................................................................................... 9 I. INTRODUCTION ...................................................................................... 10 II. REVIEW OF THE LITERATURE ............................................................ 12 1. General aspects and methodology ......................................................... 12 1.1. Diagnostic accuracy ....................................................................... 12 1.2. Criteria, clinical characteristics and classifications........................ 13 1.2.1. Criteria for the activeness of epilepsy ................................
    [Show full text]
  • New Therapeutic Agents Marketed in 2015: Part 4 Amy M
    CPE New therapeutic agents marketed in 2015: Part 4 Amy M. Lugo and Brian Park Amy M. Lugo, PharmD, BCPS, BC-ADM, Abstract FAPhA, Clinical Pharmacy Specialist, Pharmacy Operations Division, Formu- lary Management Branch, Defense Health Objective: To provide information about the most important properties of new Agency, San Antonio therapeutic agents approved by FDA and first marketed in 2015. Brian Park, PharmD candidate, University of Data sources: Product labeling supplemented selectively with published stud- New England College of Pharmacy, Portland, ies and drug information reference sources. ME Data synthesis: This review covers 11 new therapeutic agents approved by FDA Correspondence: Amy M. Lugo, 7800 and first marketed in the United States in 2015: selexipag, cobimetinib, osimertinib, IH-10 W, Ste. 335, San Antonio, TX 78230; necitumumab, alectinib, insulin degludec, lesinurad, mepolizumab, brexpiprazole, [email protected] cariprazine, and flibanserin. Indications and information on dosage and adminis- Disclosure: The authors declare no conflicts tration for these agents are reviewed, as well as efficacy, safety, the most important of interest or financial interests in any product or service mentioned in this article. pharmacokinetic properties, drug interactions, and other precautions. Practical considerations for use of these new agents also are discussed. Whenever possible, Department of Defense (DoD) disclaimer: The information discussed here represents properties of the new drugs are compared with those of older agents marketed for the views of the author and does not neces- the same indications. sarily reflect the views of DoD or the Depart- Summary: Selexipag is the second oral prostacyclin agonist for the treatment ments of the Army, Navy, or Air Force.
    [Show full text]
  • The Total Synthesis of Securinine and Other Methodology Studies
    University of Windsor Scholarship at UWindsor Electronic Theses and Dissertations Theses, Dissertations, and Major Papers 2010 The total synthesis of securinine and other methodology studies Bhartesh Dhudshia University of Windsor Follow this and additional works at: https://scholar.uwindsor.ca/etd Recommended Citation Dhudshia, Bhartesh, "The total synthesis of securinine and other methodology studies" (2010). Electronic Theses and Dissertations. 8275. https://scholar.uwindsor.ca/etd/8275 This online database contains the full-text of PhD dissertations and Masters’ theses of University of Windsor students from 1954 forward. These documents are made available for personal study and research purposes only, in accordance with the Canadian Copyright Act and the Creative Commons license—CC BY-NC-ND (Attribution, Non-Commercial, No Derivative Works). Under this license, works must always be attributed to the copyright holder (original author), cannot be used for any commercial purposes, and may not be altered. Any other use would require the permission of the copyright holder. Students may inquire about withdrawing their dissertation and/or thesis from this database. For additional inquiries, please contact the repository administrator via email ([email protected]) or by telephone at 519-253-3000ext. 3208. The Total Synthesis of Securinine and Other Methodology Studies by Bhartesh Dhudshia A Dissertation Submitted to the Faculty of Graduate Studies through the Department of Chemistry and Biochemistry in Partial Fulfillment of the Requirements
    [Show full text]
  • Classification Decisions Taken by the Harmonized System Committee from the 47Th to 60Th Sessions (2011
    CLASSIFICATION DECISIONS TAKEN BY THE HARMONIZED SYSTEM COMMITTEE FROM THE 47TH TO 60TH SESSIONS (2011 - 2018) WORLD CUSTOMS ORGANIZATION Rue du Marché 30 B-1210 Brussels Belgium November 2011 Copyright © 2011 World Customs Organization. All rights reserved. Requests and inquiries concerning translation, reproduction and adaptation rights should be addressed to [email protected]. D/2011/0448/25 The following list contains the classification decisions (other than those subject to a reservation) taken by the Harmonized System Committee ( 47th Session – March 2011) on specific products, together with their related Harmonized System code numbers and, in certain cases, the classification rationale. Advice Parties seeking to import or export merchandise covered by a decision are advised to verify the implementation of the decision by the importing or exporting country, as the case may be. HS codes Classification No Product description Classification considered rationale 1. Preparation, in the form of a powder, consisting of 92 % sugar, 6 % 2106.90 GRIs 1 and 6 black currant powder, anticaking agent, citric acid and black currant flavouring, put up for retail sale in 32-gram sachets, intended to be consumed as a beverage after mixing with hot water. 2. Vanutide cridificar (INN List 100). 3002.20 3. Certain INN products. Chapters 28, 29 (See “INN List 101” at the end of this publication.) and 30 4. Certain INN products. Chapters 13, 29 (See “INN List 102” at the end of this publication.) and 30 5. Certain INN products. Chapters 28, 29, (See “INN List 103” at the end of this publication.) 30, 35 and 39 6. Re-classification of INN products.
    [Show full text]
  • PHARMACEUTICAL APPENDIX to the TARIFF SCHEDULE 2 Table 1
    Harmonized Tariff Schedule of the United States (2020) Revision 19 Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE Harmonized Tariff Schedule of the United States (2020) Revision 19 Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 2 Table 1. This table enumerates products described by International Non-proprietary Names INN which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service CAS registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known.
    [Show full text]
  • Health Status and Medical Treatment of the Future Elderly: Final Report
    CHILD POLICY This PDF document was made available from www.rand.org as a public CIVIL JUSTICE service of the RAND Corporation. EDUCATION ENERGY AND ENVIRONMENT Jump down to document HEALTH AND HEALTH CARE 6 INTERNATIONAL AFFAIRS NATIONAL SECURITY The RAND Corporation is a nonprofit research POPULATION AND AGING PUBLIC SAFETY organization providing objective analysis and effective SCIENCE AND TECHNOLOGY solutions that address the challenges facing the public SUBSTANCE ABUSE and private sectors around the world. TERRORISM AND HOMELAND SECURITY TRANSPORTATION AND INFRASTRUCTURE Support RAND Purchase this document Browse Books & Publications Make a charitable contribution For More Information Visit RAND at www.rand.org Explore RAND Health View document details Limited Electronic Distribution Rights This document and trademark(s) contained herein are protected by law as indicated in a notice appearing later in this work. This electronic representation of RAND intellectual property is provided for non-commercial use only. Permission is required from RAND to reproduce, or reuse in another form, any of our research documents for commercial use. This product is part of the RAND Corporation technical report series. Reports may include research findings on a specific topic that is limited in scope; present discus- sions of the methodology employed in research; provide literature reviews, survey instruments, modeling exercises, guidelines for practitioners and research profes- sionals, and supporting documentation; or deliver preliminary findings. All RAND reports undergo rigorous peer review to ensure that they meet high standards for re- search quality and objectivity. Health Status and Medical Treatment of the Future Elderly Final Report Dana P. Goldman, Paul G.
    [Show full text]
  • (12) United States Patent (10) Patent No.: US 6,264,917 B1 Klaveness Et Al
    USOO6264,917B1 (12) United States Patent (10) Patent No.: US 6,264,917 B1 Klaveness et al. (45) Date of Patent: Jul. 24, 2001 (54) TARGETED ULTRASOUND CONTRAST 5,733,572 3/1998 Unger et al.. AGENTS 5,780,010 7/1998 Lanza et al. 5,846,517 12/1998 Unger .................................. 424/9.52 (75) Inventors: Jo Klaveness; Pál Rongved; Dagfinn 5,849,727 12/1998 Porter et al. ......................... 514/156 Lovhaug, all of Oslo (NO) 5,910,300 6/1999 Tournier et al. .................... 424/9.34 FOREIGN PATENT DOCUMENTS (73) Assignee: Nycomed Imaging AS, Oslo (NO) 2 145 SOS 4/1994 (CA). (*) Notice: Subject to any disclaimer, the term of this 19 626 530 1/1998 (DE). patent is extended or adjusted under 35 O 727 225 8/1996 (EP). U.S.C. 154(b) by 0 days. WO91/15244 10/1991 (WO). WO 93/20802 10/1993 (WO). WO 94/07539 4/1994 (WO). (21) Appl. No.: 08/958,993 WO 94/28873 12/1994 (WO). WO 94/28874 12/1994 (WO). (22) Filed: Oct. 28, 1997 WO95/03356 2/1995 (WO). WO95/03357 2/1995 (WO). Related U.S. Application Data WO95/07072 3/1995 (WO). (60) Provisional application No. 60/049.264, filed on Jun. 7, WO95/15118 6/1995 (WO). 1997, provisional application No. 60/049,265, filed on Jun. WO 96/39149 12/1996 (WO). 7, 1997, and provisional application No. 60/049.268, filed WO 96/40277 12/1996 (WO). on Jun. 7, 1997. WO 96/40285 12/1996 (WO). (30) Foreign Application Priority Data WO 96/41647 12/1996 (WO).
    [Show full text]
  • Pharmacology on Your Palms CLASSIFICATION of the DRUGS
    Pharmacology on your palms CLASSIFICATION OF THE DRUGS DRUGS FROM DRUGS AFFECTING THE ORGANS CHEMOTHERAPEUTIC DIFFERENT DRUGS AFFECTING THE NERVOUS SYSTEM AND TISSUES DRUGS PHARMACOLOGICAL GROUPS Drugs affecting peripheral Antitumor drugs Drugs affecting the cardiovascular Antimicrobial, antiviral, Drugs affecting the nervous system Antiallergic drugs system antiparasitic drugs central nervous system Drugs affecting the sensory Antidotes nerve endings Cardiac glycosides Antibiotics CNS DEPRESSANTS (AFFECTING THE Antihypertensive drugs Sulfonamides Analgesics (opioid, AFFERENT INNERVATION) Antianginal drugs Antituberculous drugs analgesics-antipyretics, Antiarrhythmic drugs Antihelminthic drugs NSAIDs) Local anaesthetics Antihyperlipidemic drugs Antifungal drugs Sedative and hypnotic Coating drugs Spasmolytics Antiviral drugs drugs Adsorbents Drugs affecting the excretory system Antimalarial drugs Tranquilizers Astringents Diuretics Antisyphilitic drugs Neuroleptics Expectorants Drugs affecting the hemopoietic system Antiseptics Anticonvulsants Irritant drugs Drugs affecting blood coagulation Disinfectants Antiparkinsonian drugs Drugs affecting peripheral Drugs affecting erythro- and leukopoiesis General anaesthetics neurotransmitter processes Drugs affecting the digestive system CNS STIMULANTS (AFFECTING THE Anorectic drugs Psychomotor stimulants EFFERENT PART OF THE Bitter stuffs. Drugs for replacement therapy Analeptics NERVOUS SYSTEM) Antiacid drugs Antidepressants Direct-acting-cholinomimetics Antiulcer drugs Nootropics (Cognitive
    [Show full text]
  • Stems for Nonproprietary Drug Names
    USAN STEM LIST STEM DEFINITION EXAMPLES -abine (see -arabine, -citabine) -ac anti-inflammatory agents (acetic acid derivatives) bromfenac dexpemedolac -acetam (see -racetam) -adol or analgesics (mixed opiate receptor agonists/ tazadolene -adol- antagonists) spiradolene levonantradol -adox antibacterials (quinoline dioxide derivatives) carbadox -afenone antiarrhythmics (propafenone derivatives) alprafenone diprafenonex -afil PDE5 inhibitors tadalafil -aj- antiarrhythmics (ajmaline derivatives) lorajmine -aldrate antacid aluminum salts magaldrate -algron alpha1 - and alpha2 - adrenoreceptor agonists dabuzalgron -alol combined alpha and beta blockers labetalol medroxalol -amidis antimyloidotics tafamidis -amivir (see -vir) -ampa ionotropic non-NMDA glutamate receptors (AMPA and/or KA receptors) subgroup: -ampanel antagonists becampanel -ampator modulators forampator -anib angiogenesis inhibitors pegaptanib cediranib 1 subgroup: -siranib siRNA bevasiranib -andr- androgens nandrolone -anserin serotonin 5-HT2 receptor antagonists altanserin tropanserin adatanserin -antel anthelmintics (undefined group) carbantel subgroup: -quantel 2-deoxoparaherquamide A derivatives derquantel -antrone antineoplastics; anthraquinone derivatives pixantrone -apsel P-selectin antagonists torapsel -arabine antineoplastics (arabinofuranosyl derivatives) fazarabine fludarabine aril-, -aril, -aril- antiviral (arildone derivatives) pleconaril arildone fosarilate -arit antirheumatics (lobenzarit type) lobenzarit clobuzarit -arol anticoagulants (dicumarol type) dicumarol
    [Show full text]